Galiximab
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors[1][2].
Product Specifications
CAS Number
357613-77-5
Product Name Alternative
IDEC 114; Anti-Human CD80 Recombinant Antibody
UNSPSC
12352203
Target
Apoptosis; CD28
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/galiximab.html
Purity
99.23
Solubility
10 mM in DMSO
Smiles
[Galiximab]
Molecular Weight
(145.24 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human JAKMIP2 sgRNA gene knockout kit - Lentiviral human JAKMIP2 sgRNA gene knockout kit (25)
Phospho-MAPKAPK2 (Thr222) Rabbit Polyclonal Antibody (PE-Cy7)
NSE4A, NT (NSMCE4A, C10orf86, Non-structural maintenance of chromosomes element 4 homolog A)